Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Total Non-Current Liabilities (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 37.5% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 37.5% decrease, with the full-year FY2024 number at $3.6 million, down 34.05% from a year prior.
  • Total Non-Current Liabilities was $1.8 million for Q3 2025 at NovaBay Pharmaceuticals, down from $2.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $13.2 million in Q4 2021 to a low of $1.8 million in Q3 2025.
  • A 5-year average of $5.3 million and a median of $5.0 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 353.63% in 2021, then crashed 55.87% in 2022.
  • NovaBay Pharmaceuticals' Total Non-Current Liabilities stood at $13.2 million in 2021, then plummeted by 55.87% to $5.8 million in 2022, then decreased by 7.85% to $5.4 million in 2023, then crashed by 34.05% to $3.6 million in 2024, then plummeted by 50.65% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Total Non-Current Liabilities are $1.8 million (Q3 2025), $2.6 million (Q2 2025), and $3.6 million (Q1 2025).